Gossamer Bio (GOSS): which funds own it
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Sections with a free account
5 concentrated managers hold it (+1 vs last quarter) with a median weight of 0.1%.
Who owns Gossamer Bio?
Holders that filed a Schedule 13D or 13G with the SEC for owning more than 5% of the shares: 683 Capital Management (13G filed Jun 11, 2026), Context Capital Management (13G filed Jun 9, 2026), DeepCurrents Investment Group (13G filed Jun 11, 2026), D. E. Shaw (13D/A filed Jul 24, 2026) and D. E. Shaw (13D/A filed Aug 24, 2026). As of Jun 30, 2026, the largest holders reported on Form 13F were D. E. Shaw (41.0 million shares), 683 Capital Management (39.2 million shares) and DeepCurrents Investment Group (37.7 million shares).
Which institutions hold the most Gossamer Bio shares?
Per Form 13F filings as of Jun 30, 2026:
- 1. D. E. Shaw: 41.0 million shares
- 2. 683 Capital Management: 39.2 million shares
- 3. DeepCurrents Investment Group: 37.7 million shares
- 4. Context Capital Management: 28.9 million shares
- 5. Worth Venture Partners: 25.0 million shares
- 6. AQR Capital Management: 15.6 million shares
- 7. GSA Capital Partners LLP: 15.0 million shares
- 8. Wolverine Asset Management: 12.9 million shares
- 9. Renaissance Technologies: 11.6 million shares
- 10. Kalehua Capital Management: 11.1 million shares
Sources:13G by 683 Capital Management (Jun 11, 2026) ↗13G by Context Capital Management (Jun 9, 2026) ↗13G by DeepCurrents Investment Group (Jun 11, 2026) ↗13D/A by D. E. Shaw (Jul 24, 2026) ↗13D/A by D. E. Shaw (Aug 24, 2026) ↗All of the company's proxy statements on EDGAR ↗
We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.
Gossamer Bio revenue
Gossamer Bio reported annual revenue of $48.5 million for fiscal year 2025 (year ended December 31, 2025), according to its Form 10-K filed with the SEC (XBRL data).
Quarter flow (concentrated managers)
Change in managers (4 → 5): 1 opened · 0 exited = +1
Net flow in the quarter: +$11K (+68 K shares) · bought $11K and sold $0Shares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.
The set of concentrated managers changed between quarters: with the set as it was then, 3 held it last quarter (the chart point); with today's set, 4 (the base for the change).
Concentrated managers holding it
- Octagon Capital Advisors$1.3M0.1%
- Samsara Biocapital$1.2M0.1%
- Hhlr Advisors$819K0.1%
- Bronte Capital Management PtyNew$11.2K0.0%+0.0 pp
- Skaana Management$6.6K0.0%
Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.
Largest holders of GOSS (all 13F filers)
- D. E. Shaw41.0 MQuant or multi-manager · 8.38% of the company+40.6 M
- 683 Capital Management39.2 MType not verified · 8.02% of the company+34.2 M
- DeepCurrents Investment Group37.7 MType not verified · 7.70% of the company+37.7 M
- Context Capital Management28.9 MType not verified · 5.92% of the company+28.9 M
- Worth Venture Partners25.0 MType not verified · 5.12% of the company+25.0 M
- AQR Capital Management15.6 MQuant or multi-manager · 3.20% of the company+5.5 M
- GSA Capital Partners LLP15.0 MType not verified · 3.07% of the company+11.7 M
- Wolverine Asset Management12.9 MType not verified · 2.64% of the company+12.9 M
- Renaissance Technologies11.6 MQuant or multi-manager · 2.38% of the company+10.4 M
- Kalehua Capital Management11.1 MType not verified · 2.28% of the company+913 K
- Shares
- 41.0 M
- Change
- +40.6 M
- % of the company
- 8.38%
See more
- Type
- Quant or multi-manager
- Value
- $6.7M
- Shares
- 39.2 M
- Change
- +34.2 M
- % of the company
- 8.02%
See more
- Type
- Type not verified
- Value
- $6.5M
- DeepCurrents Investment Group
- Shares
- 37.7 M
- Change
- +37.7 M
- % of the company
- 7.70%
See more
- Type
- Type not verified
- Value
- $6.0M
- Context Capital Management
- Shares
- 28.9 M
- Change
- +28.9 M
- % of the company
- 5.92%
See more
- Type
- Type not verified
- Value
- $4.8M
- Worth Venture Partners
- Shares
- 25.0 M
- Change
- +25.0 M
- % of the company
- 5.12%
See more
- Type
- Type not verified
- Value
- $4.1M
- Shares
- 15.6 M
- Change
- +5.5 M
- % of the company
- 3.20%
See more
- Type
- Quant or multi-manager
- Value
- $2.6M
- Shares
- 15.0 M
- Change
- +11.7 M
- % of the company
- 3.07%
See more
- Type
- Type not verified
- Value
- $2.5M
- Shares
- 12.9 M
- Change
- +12.9 M
- % of the company
- 2.64%
See more
- Type
- Type not verified
- Value
- $2.1M
- Shares
- 11.6 M
- Change
- +10.4 M
- % of the company
- 2.38%
See more
- Type
- Quant or multi-manager
- Value
- $1.9M
- Kalehua Capital Management
- Shares
- 11.1 M
- Change
- +913 K
- % of the company
- 2.28%
See more
- Type
- Type not verified
- Value
- $1.8M
The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.
Fundamentals
12-month figures to Jun 30, 2026 · balance sheet as of Jun 30, 2026.
- Operating margin
- —
- Net margin
- —
- ROE
- —
- Revenue (TTM)
- $53.3M
- Revenue growth
- 32.4%
- Net income (TTM)
- $-125M
- Net debt / EBITDA
- —
- Free cash flow (TTM)
- $-163M
- Quality vs sector
- —
This company's sector comes from its SIC code, unreviewed, or has too few comparable companies: we do not compare it with its sector.
Figures from the statements the company filed with the SEC (10-K, 10-Q). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated
Shares outstanding: buybacks and dilution
2025: 228.5 M
- 1 year
- +1.0%
- 3 years
- +170.2%
- 5 years
- +233.6%
- Buybacks (FY 2025)
- no data
- Share issuance
- no data
- Stock-based compensation
- $10.6M21.8% of revenue
- Dividends paid
- no data
From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.
Earnings quality and debt
- Operating cash flow ÷ net income (12 months)
- no datanot calculated with negative net income
- Interest coverage (operating income ÷ interest)
- −15.5 timesnegative operating income
- Debt due within 12 months
- $36.1M0.63 times cash and investments
From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.
Insiders (Form 4)
10% owners who bought (6 m): 0
Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.
Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →
Above 5% (13D/13G)
Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.
This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.
- D. E. Shaw6%13D · amendmentfiling ↗Event: Aug 20, 2026 · filed: Aug 24, 2026
- BlackRock1%(fell below 5%)13G · amendmentfiling ↗Event: Jun 30, 2026 · filed: Jul 29, 2026
- Opaleye Management5.1%13Gfiling ↗Event: Jul 22, 2026 · filed: Jul 29, 2026
Above 5% over time (13D/13G)
Each holder with its filings in order. History since December 2024.
Flagged material events (8-K)
Notice of delisting or failure to meet a listing rule (Item 3.01)
Change in directors or officers (Item 5.02)
«Gossamer Bio Appoints Greg Ciongoli to Board of Directors»
Unregistered sale of equity securities (Item 3.02)
«Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA…»
Change in directors or officers (Item 5.02)
Unregistered sale of equity securities (Item 3.02)
«Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes»
Change in directors or officers (Item 5.02)
Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.
All material events (8-K)
Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.
Other Health Care stocks in managers' portfolios
Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.
- Anteris Technologies GlobalAVR · 5 managers
- Compass TherapeuticsCMPX · 5 managers
- Crinetics PharmaceuticalsCRNX · 5 managers
- IncyteINCY · 5 managers
- Summit TherapeuticsSMMT · 5 managers
- Achieve Life SciencesACHV · 6 managers